Pharmaceutical composition for treating heart failure with preserved ejection fraction and application of pharmaceutical composition
A heart failure and ejection fraction technology, applied in the field of medicine, can solve the problems of reducing myocardial infarction size and increasing the release of vascular endothelial relaxation factors, and achieve the effect of increasing patient compliance, reducing treatment costs, and reducing drug resistance.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Example Embodiment
[0019] Example 1
[0020] 15 healthy Wistar male rats, weighing 200-220 g. After one week of adaptive rearing of the rats, 3 rats were randomly selected as the sham-operated group (the sham-operated group had the surgical silk thread passed through the abdominal aorta after laparotomy, but the abdominal aorta was not ligated), and the remaining 12 rats underwent abdominal surgery as follows: Aortic coarctation surgery to establish an animal model of heart failure with preserved ejection fraction: after skin preparation, rats were anesthetized with 3% sodium pentobarbital at 2.3ml / kg intraperitoneal anesthesia. The abdominal aorta was bluntly dissociated below the branch of the renal artery, the needle of a 9-gauge syringe was placed parallel to the abdominal artery, the abdominal aorta and the needle were ligated together with a 4-gauge surgical silk thread, and then the needle was slowly withdrawn to make the abdominal aorta of the rat The diameter is reduced by 35% to 40%, ...
Example Embodiment
[0028] Embodiment 2
[0029] The method is the same as in Example 1, except that the Alda-1 group is administered with 6 mg / kg of Alda-1 every day; the combination group is administered with 3 mg / kg of Alda-1 and 15 mg / kg of isosorbide mononitrate every day. .
[0030]The left ventricular systolic pressure and left ventricular end-diastolic pressure were detected by hemodynamics. The statistical results are shown in Table 1. Cardiac hypertrophy index was used to measure global cardiac mass index and left ventricular mass index. The statistical results are shown in Table 2.
[0031] It should be noted that, because the rats in the model control group did not take any treatment measures, the symptoms of heart failure gradually aggravated, and all died after 5 days. The Alda-1 group did not significantly improve the symptoms of heart failure in the rats. The heart failure symptoms of the rats in the combination group were significantly improved, and the concomitant symptoms of ...
Example Embodiment
[0039] Embodiment 3
[0040] The method is the same as that in Example 1, except that the Alda-1 group is administered with 90 mg / kg of Alda-1 every day; the combination group is administered with 45 mg / kg of Alda-1 and 15 mg / kg of isosorbide mononitrate. .
[0041] The left ventricular systolic pressure and left ventricular end-diastolic pressure were detected by hemodynamics. The statistical results are shown in Table 1. Cardiac hypertrophy index was used to measure global cardiac mass index and left ventricular mass index. The statistical results are shown in Table 2.
[0042] It should be noted that, because the rats in the model control group did not take any treatment measures, the symptoms of heart failure gradually aggravated, and all died after 10 days. The Alda-1 group did not significantly improve the symptoms of heart failure in the rats. The heart failure symptoms of the rats in the combination group were significantly improved, and the concomitant symptoms of h...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap